The performance of companies tied to blockbuster drugs like Viagra presents a nuanced investment landscape . While the initial surge of copyright, fueled by Viagra's remarkable popularity, generated substantial profits , the expiry in key territories has introduced considerable risk . Investors are now facing the consequences of generic competition